PubMed 22558454

Referenced in: none

Automatically associated channels: Cav1.2 , Cav3.1 , Kv1.1 , Kv1.2 , Kv1.3 , Kv1.4 , Kv1.5 , Kv11.1 , Kv7.1 , Nav1.5

Title: The antibody targeting the e314 Peptide of human kv1.3 pore region serves as a novel, potent and specific channel blocker.

Authors: Xiao-Fang Yang, Yong Yang, Yi-Tian Lian, Zhao-Hui Wang, Xiao-Wei Li, Long-xian Cheng, Jin-Ping Liu, Yan-Fu Wang, Xiang Gao, Yu-hua Liao, Min Wang, Qiu-tang Zeng, Kun Liu

Journal, date & volume: PLoS ONE, 2012 , 7, e36379

PubMed link: http://www.ncbi.nlm.nih.gov/pubmed/22558454

Abstract
Selective blockade of Kv1.3 channels in effector memory T (T(EM)) cells was validated to ameliorate autoimmune or autoimmune-associated diseases. We generated the antibody directed against one peptide of human Kv1.3 (hKv1.3) extracellular loop as a novel and possible Kv1.3 blocker. One peptide of hKv1.3 extracellular loop E3 containing 14 amino acids (E314) was chosen as an antigenic determinant to generate the E314 antibody. The E314 antibody specifically recognized 63.8KD protein stably expressed in hKv1.3-HEK 293 cell lines, whereas it did not recognize or cross-react to human Kv1.1(hKv1.1), Kv1.2(hKv1.2), Kv1.4(hKv1.4), Kv1.5(hKv1.5), KCa3.1(hKCa3.1), HERG, hKCNQ1/hKCNE1, Nav1.5 and Cav1.2 proteins stably expressed in HEK 293 cell lines or in human atrial or ventricular myocytes by Western blotting analysis and immunostaining detection. By the technique of whole-cell patch clamp, the E314 antibody was shown to have a directly inhibitory effect on hKv1.3 currents expressed in HEK 293 or Jurkat T cells and the inhibition showed a concentration-dependence. However, it exerted no significant difference on hKv1.1, hKv1.2, hKv1.4, hKv1.5, hKCa3.1, HERG, hKCNQ1/hKCNE1, L-type Ca(2+) or voltage-gated Na(+) currents. The present study demonstrates that the antibody targeting the E314 peptide of hKv1.3 pore region could be a novel, potent and specific hKv1.3 blocker without affecting a variety of closely related K(v)1 channels, KCa3.1 channels and functional cardiac ion channels underlying central nervous system (CNS) disorders or drug-acquired arrhythmias, which is required as a safe clinic-promising channel blocker.